Am J Psychiatry 1978; 135:467-469
Copyright © 1978 by American Psychiatric Association
Acetylation phenotype, platelet monoamine oxidase inhibition, and the effectiveness of phenelzine in depression
J Davidson, MN McLeod and MR Blum
The authors treated 16 depressed patients with up to 90 mg/day of
phenelzine. After acetylation phenotype was determined and platelet
monoamine oxidase (MAO) activity measured, no significant relationship was
observed between clinical improvement and acetylation phenotype or between
MAO inhibition and acetylation. Discrepant findings regarding acetylation
phenotype and the effects of phenelzine are discussed. The authors do not
recommend a sulfamethazine phenotype test as a predictor of outcome for
phenelzine.
